Gregory W. Fulton Neuromuscular Center
The purpose of this study is to evaluate the efficacy and safety of Ravulizumab, which is being developed to treat generalized myasthenia gravis by blocking abnormal complement activity, which is the part of the immune system that fights against infections. Ravulizumab is administered via intravenous infusions over a 26-week treatment period (i.e. two loading doses administered approximately once 2 weeks apart, followed by 2 maintenance doses administered approximately 8 weeks apart).
In addition to the study drug infusions, participants will complete study visits to assess clinical outcomes on a weekly basis for the first month, then bi-weekly for about two months, and finally monthly for the last three months.
Overall, participants will be in the research study for approximately 26 weeks, with the option to continue for up to 2 years in an open label extension study.
Principal Investigator: Suraj Muley, MD